Chapter 4. Pharmacogenetics of Mitochondrial Drug Toxicity

  1. James A. Dykens3,
  2. Yvonne Will4
  1. Neil Howell1,
  2. Corinna Howell2

Published Online: 22 JAN 2008

DOI: 10.1002/9780470372531.ch4

Book Title

Drug-Induced Mitochondrial Dysfunction

Drug-Induced Mitochondrial Dysfunction

Additional Information

How to Cite

Howell, N. and Howell, C. (2008) Pharmacogenetics of Mitochondrial Drug Toxicity, in Drug-Induced Mitochondrial Dysfunction (eds J. A. Dykens and Y. Will), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470372531.ch4

Editor Information

  1. 3

    Pfizer, Inc., Sandwich, UK

  2. 4

    Pfizer, Inc., Groton, Connecticut, USA

Author Information

  1. 1

    MIGENIX Corporation, San Diego, California; currently at Matrilinex LLC, San Diego, California, USA

  2. 2

    Matrilinex LLC, San Diego, California, USA

Publication History

  1. Published Online: 22 JAN 2008
  2. Published Print: 14 SEP 2008

ISBN Information

Print ISBN: 9780470111314

Online ISBN: 9780470372531

SEARCH

CHAPTER TOOLS

Get PDF (187K)

Keywords:

  • mitochondrial drug toxicity and mitochondrial pharmacogenetic utility;
  • mitochondrial drug toxicity pharmacogenetics;
  • 16189 mutation and T2D risk factor

Summary

This chapter contains sections titled:

  • Introduction

  • Mitochondrial DNA mutations, aminoglycosides, and deafness

  • Disputed Role of 16189 mtDNA polymorphism in type 2 diabetes

  • Conclusions

  • References

Get PDF (187K)